Abstract
It is now well accepted that host defense mechanisms, both cellular and humoral, are regulated by a family of cytokines, interleukins and colony-stimulating factors (CSFs). Control of antibody production and humoral immunity including antigen processing, T-cell and B-cell responses and the proliferation of plasma cells are under the control of Interleukin-2 (IL-2) through IL-17. Naturally occurring diseases and gene “knockout” experiments in mice clearly indicate the essential roles for some of these factors and their receptors in maintaining humoral immunity [1], Similarly, cellular immunity, largely mediated through T-cells, is under the control of the interleukins, and mediated through specific cell surface receptors for these factors. Although our understanding of interleukins in humoral and cellular host defense mechanisms is advancing rapidly, clinical applications of interleukins to modify in vivo lymphocyte mediated responses is still largely at the investigative stage. Interesting potential clinical applications include the use of IL-2 to treat HIV infected individuals [2], the use of autologous IL-2 expanded cells for prevention of cytomegalovirus infections in bone marrow transplant patients [3], and potential applications of IL-10 to modify the suppressor/helper functions of lymphocytes in a variety of inflammatory and infectious diseases [4]. The interferons, well characterized cytokines produced in response to many viral infections, can also be used pharmacologically to modify the course of hepatitis B, hepatitis C, and some other infections as outlined in recent reviews [5,6].
Keywords
- Visceral Leishmaniasis
- Bone Marrow Transplant Patient
- Haematopoietic Growth Factor
- Neutrophil Production
- Chronic Neutropenia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Murray R. Physiologic roles of interleukin-2, interleukin-4, and interleukin-7. Cur Opn Hematol 1996;3:230–34.
Kovacs JA, Baseler M, Dewar RJ et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567–75.
Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038–44.
Geissler K. Current status of clinical development of interleukin-10. Cur Opn Hematol 1996;3:203–08.
Gallin JI, Färber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995;123:216–24.
Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994; 39:241–75.
Sachs L. The control of hematopoiesis and leukemia: From basic biology to the clinic. Proc Natl Acad Sci USA 1996;93:4742–49.
Metcalf D. The role of the colony-stimulating factors in resistance to acute infections. Immunol Cell Biol 1987;65(Pt. l):35–43.
Cheers C, Haigh AM, Kelso A, et al. Production of colony-stimulating factors (CSFs) during infection: Separate determinations of macrophage-, granulocyte-, and multi-CSFs. Infection and Immunity 1988;56:247–51.
Nicola NA, Metcalf D, Johnson GR, Burgess AW. Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors. Blood 1979;54:614–27.
Nicola NA, Metcalf D, Matsumoto M, Johnson GR: Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. J Biol Chem 1983;258:9017–23.
Dinarello CA. Biologic basis for interleukin-l in disease. Blood 1996;87:2095–147.
Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, parts I and II. N Engl J Med 1992;327:(I)28–35,(11)99–106.
Cebon J, Layton J. Measurement and clinical significance of circulating hematopoietic growth factor levels. Curr Opn Hematol 1994; 1:228–34.
Cebon J, Layton J, Maher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Brit J Haematol 1994;86:265–74.
Metcalf D. Hematopoietic regulators: Redundancy or subtlety? Blood 1993;82:3515–23.
Hermann JL, Blanchard H, Brunengo P, Lagrange PH. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 1994;22:309–15.
Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J Infect Dis 1995;172:296–301.
Waring PM, Presneill J, Maher DW, et al. Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 1995;102: 501–06.
Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infec Dis 1995;171:145–52.
Taveira Da Silva AMT, Kaulbach HC, Chuidian FS, et al. Brief report: Shock and multiple-organ dysfunction after self-administration of salmonella endotoxin. N Engl J Med 1993;328:1457–60.
Dale DC, Lau S, Nash R, Boone T, Osborne W. The effect of endotoxin on serum granulocyte and granulocyte-macrophage colony stimulating factor (G-CSF and GM-CSF) levels in dogs. J Inf Dis 1991;87:704–10.
Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990;76:1962–64.
Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994;84:1737–46.
Hammond WP, Csiba E, Canin A, Souza LM, Dale DC. Chronic neutropenia: A new canine model induced by human G-CSF. J Clin Invest 1991;87:704–10.
Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994;294:713–16.
Price TH, Chatta GS, Dale DC. The effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996;88:335–40.
Dale DC, Liles WC, Summer W, Nelson S. Granulocyte-colony-stimulating factor: Role and relationships in infectious diseases. J Inf Dis 1995;172:1061–75.
Kerst JM, de Haas M, van der Schoot CE, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: Induction of immunopheno-typically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993;82:3265–72.
Repp R, Valerius T, Sendler A, et al. Neutrophils express the high affinity receptor for IgG (FcγRI; CD64) after in vivo application of rhG-CSF. Blood 1991;78:885–89.
Kerst JM, van de Winkel JGJ, Evans AH, et al. Granulocyte colony-stimulating factor induces hFcγRI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 1993;81:1457–64.
Colotta F, Re F, Polentarutti N, et al. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992;80:2012–20.
Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989;83:551–57.
Hill ADK, Naama HA, Calvano SE, Daly JM. The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. J Leuko Biol 1995;58:634–42.
Cairo MS, Mauss D, Kommareedy S, et al. Prophylactic or simultaneous administration of recombinant human granulocyte colony-stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats. Pediatr Res 1990;27:612–16.
Liechty KW, Schibler KR, Ohls RK, et al. The failure of newborn mice infected with Escherichia coli to accelerate neutrophil production correlates with their failure to increase transcripts for granulocyte colony-stimulating factor and interleukin-6. Biol Neonate 1993;64:331–40.
Cairo MS, Plunkett JM, Mauss D, van de Ven C. Seven-day administration of recombinant human granulocyte colony-stimulating factor to newborn rats: Modulation of neonatal neutrophilia, myelopoiesis, and group B Streptococcus sepsis. Blood 1990; 76:1788–94.
Herbert JC, O’Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 1990;125:1075–78.
Toda H, Murata A, Oka Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood 1994;83:2893–98.
Eichacker PQ, Waisman Y, Natanson C, et al. Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appli Physiol 1994; 77:2366–73.
Nelson S, Summer W, Bagby G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991; 164:901–06.
Lister PD, Gentry MJ, Preheim LC. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993;168:922–26.
Mooney DP, Gamelli RL, O’Reilly M, Hebert JC. Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg 1988; 123: 1353–57.
Silver GM, Gamelli RL, O’Reilly M. The beneficial effect of granulocyte colony-stimulating factor (G-CSF) on survival after Pseudomonas burn wound infection. Surgery 1989;106:452–56.
Jyung RW, Wu L, Pierce GF, Mustoe TA. Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: Differential action on incisional wound healing. Surgery 1994; 115:325–34.
Fink MP, O’Sullivan BP, Menconi M J, et al. Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. J Trauma 1993; 34:571–78.
Koizumi T, Kubo K, ShinozakiS, et al. Granulocyte colony-stimulating factor does not exacerbate endotoxin-induced lung injury in sheep. Am Rev Respir Dis 1993; 148:132–37.
Kanazawa M, Ishizaka A, Hasegawa N, et al. Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. Am Rev Respir Dis 1992;145:1030–35.
Ozer H (for Am Soc Clin Oncol ad hoc CSSF Guidelines Expert Panel) American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–508.
Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia. Blood 1993; 81:2496–502.
Frumkin L, Dale DC. The role of colony-stimulating factors in HIV disease. The Aids Reader 1996;Nov/Dec 185–93.
Keiser P, Rademacher S. G-CSF use is associated with decreased bacteremia and increased survival in neutropenic, HIV infected patients. 3rd Conference on retrovirus and opportunistic infections. Washington DC 1996:abstract 518.
DeBoisblanc B, Summer WR, Mason C, Shellito J, Andresen J, Nelson S. A phase I trial of granulocyte colony-stimulating factor in severe community-acquired pnemonia Am Rev Resp Dis 1993; 147(4):A204.
Nelson S, Farkas S, Fotheringham N, Ho H, Mattie T, Movahhed H. Filgrastim in the treatment of hospitalized patients with community acquired pneumonia. Am J Crit Care Med 1996;153:A535.
Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental leishmaniasis. J Clin Invest 1995;95:1183–92.
Badar’o R, Nascimento C, Carvalho JS, et al. Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. Eur J Clin Microbiol Infect Dis 1994;3:S23–28.
Badar’o R, Nascimento C, Carvalho JS, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 1994;170:413–18.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Dale, D.C. (1997). Cytokines in the Treatment of Infection. In: Sibinga, C.T.S., Das, P.C., Löwenberg, B. (eds) Cytokines and Growth Factors in Blood Transfusion. Developments in Hematology and Immunology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1137-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1137-9_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8435-2
Online ISBN: 978-1-4613-1137-9
eBook Packages: Springer Book Archive